文章：

胰腺导管腺癌免疫抑制微环境中靶向肿瘤相关巨噬细胞的策略

Strategies to Target the Tumor-Associated Macrophages in the Immunosuppressive Microenvironment of Pancreatic Ductal Adenocarcinoma

原文发布日期：22 September 2025

DOI: 10.3390/cancers17183090

类型: Article

开放获取: 是

英文摘要：

Pancreatic ductal adenocarcinoma (PDAC) is a critical disease requiring the development of novel effective therapeutic approaches due to its increasing global incidence and associated low survival rates. While immunotherapy, including immune checkpoint inhibitors, has shown efficacy against various tumors, developing an effective treatment approach for PDAC poses a challenge. This is primarily attributed to the complex and distinctive immune evasion mechanisms of PDAC. Recent studies have revealed that tumor-associated macrophages (TAMs) play a crucial role in enhancing immune evasion in PDAC. This role is mediated through multiple pathways, including cytokine secretion and the activation or suppression of diverse immune cells. A clear understanding of how macrophages contribute to PDAC proliferation could lead to the development of novel immune therapy approaches targeting TAMs. In this review, we summarized the multifaceted activities and roles of TAMs in PDAC and explored the potential effect of immunotherapeutic approaches on PDAC, with a particular focus on chimeric antigen receptor (CAR) macrophages. This review was based on promising findings from recent studies on CAR macrophage-based immunotherapy for solid tumors.

摘要翻译： 

胰腺导管腺癌（PDAC）是一种全球发病率持续上升且生存率较低的严重疾病，亟需开发新型有效的治疗方法。尽管以免疫检查点抑制剂为代表的免疫疗法已在多种肿瘤中显示出疗效，但针对PDAC的有效治疗策略仍面临挑战，这主要归因于PDAC复杂且独特的免疫逃逸机制。近期研究表明，肿瘤相关巨噬细胞（TAMs）通过细胞因子分泌、调控多种免疫细胞活化或抑制等多条途径，在增强PDAC免疫逃逸中发挥关键作用。明确巨噬细胞促进PDAC增殖的具体机制，有望推动针对TAMs的新型免疫疗法开发。本文综述了TAMs在PDAC中的多重功能与作用，并基于近期实体瘤嵌合抗原受体（CAR）巨噬细胞免疫疗法的突破性进展，重点探讨了以CAR巨噬细胞为代表的免疫疗法对PDAC的潜在治疗价值。

原文链接：

Strategies to Target the Tumor-Associated Macrophages in the Immunosuppressive Microenvironment of Pancreatic Ductal Adenocarcinoma